Dianthus Therapeutics (DNTH) Equity Average (2018 - 2025)
Historic Equity Average for Dianthus Therapeutics (DNTH) over the last 7 years, with Q3 2025 value amounting to $424.8 million.
- Dianthus Therapeutics' Equity Average rose 2203.9% to $424.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $424.8 million, marking a year-over-year increase of 2203.9%. This contributed to the annual value of $260.7 million for FY2024, which is 31874.59% up from last year.
- Dianthus Therapeutics' Equity Average amounted to $424.8 million in Q3 2025, which was up 2203.9% from $315.8 million recorded in Q2 2025.
- Dianthus Therapeutics' Equity Average's 5-year high stood at $424.8 million during Q3 2025, with a 5-year trough of -$56.1 million in Q2 2023.
- Its 4-year average for Equity Average is $189.9 million, with a median of $173.6 million in 2023.
- In the last 5 years, Dianthus Therapeutics' Equity Average crashed by 13914.02% in 2023 and then soared by 75096.63% in 2024.
- Over the past 4 years, Dianthus Therapeutics' Equity Average (Quarter) stood at -$39.6 million in 2022, then surged by 538.88% to $173.6 million in 2023, then skyrocketed by 98.81% to $345.2 million in 2024, then grew by 23.05% to $424.8 million in 2025.
- Its Equity Average was $424.8 million in Q3 2025, compared to $315.8 million in Q2 2025 and $340.5 million in Q1 2025.